|
|
|
|
 |
|
|
|
PhenoSense GT™ reveals more, for better treatment decisions
Choosing whether to perform a phenotype or genotype assay can be a critical decision in HIV drug resistance testing and in the management of your patient’s antiretroviral therapy. Each can provide valuable information. By combining actual phenotype with genotype, PhenoSense GT™ overcomes the limitations of either assay alone.
Choosing PhenoSense GT™ after 2 regimen failures allows you to retain options in your drug-regimen strategy and save some drug choices for a later time.
PhenoSense GT™ features and benefits:
- Updated clinical cutoff values identify drugs with partial activity against the patient virus, revealing more drug regimen options
- Resolves disagreement between actual phenotype and genotype through proprietary algorithm, database, and expert analysis
- Provides results in a single, user-friendly report with a new, easy-to-read summary page
- Net assessment provides a simple, evidence-based interpretation of results
- Supplements resistance with replication capacity (RC) to help guide your treatment choices
- Avoids complications associated with separate patient samples and separate laboratories by using just 1 patient sample and providing results of both tests in 1 report
|
|
 |
